Stem Cell Therapeutics Corp. Announces Enrollment of First Patient in the Traumatic Brain Injury Trial

CALGARY, ALBERTA--(Marketwire - April 28, 2011) - Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) ("SCT" or the "Company") is pleased to announce the enrollment of the first patient in the SCT supported Open label Phase IIa traumatic brain injury ("TBI") trial entitled "A Phase IIa, Single Center, Open Label Study to Characterize the Safety of Human Chorionic Gonadotrophin (hCG) and Epoeitin Alpha (EPO) in Traumatic Brain Injury". The principal investigator for this investigator-led clinical trial is Dr. David Zygun at the Foothills Hospital. The purpose of this trial is to characterize the safety profile of NTx®-428 when administered to patients who have sustained a TBI. Additionally, a number of secondary endpoints will be studied, these include preliminary characterization of magnetic resonance imaging, motor, cognitive and functional recovery. The trial is anticipated to complete the enrollment of 10 patients by year end 2011.

Dr. Allen Davidoff, Chief Scientific Officer of SCT commented, "We congratulate Dr. Zygun and the emergency care team at Foothills Hospital for their tireless efforts in screening that resulted in the enrollment of this first patient in the TBI trial. SCT's management is equally excited that the NTx®-428 clinical program takes an important step forward toward demonstrating the safety and effectiveness of this regimen in TBI. Broadening our knowledge of the applicability of hCG and EPO into other areas of acute neurologic injury, in addition to stroke, is anticipated to substantially increase the technology value of this program."

Dean Peterson, Chairman of the Board of SCT commented, "SCT is excited to have enrolled its first TBI patient, reaffirming the board and management's commitment to moving forward as a biotechnology company and adding value to its intellectual property portfolio. The board and SCT management are actively working on various initiatives and SCT continues to appreciate the ongoing support of its shareholders."

About Stem Cell Therapeutics Corp: Stem Cell Therapeutics Corp. is a Canadian public biotechnology company (TSX-V: SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair neurological function lost due to disease or injury. SCT's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as stroke, traumatic brain injury, multiple sclerosis, Huntington's disease, Alzheimer's disease, and ALS.

For further information on Stem Cell Therapeutics Corp., visit www.stemcellthera.com.

These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.